Xynomic pharmaceuticals holdings, inc. (XYN)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16
Operating expenses:
Research and development

3,831

1,567

-

-

1,682

3,873

-

-

-

-

-

-

General and administrative

1,128

1,443

-

-

608

745

-

-

-

-

-

-

General and administrative to related parties

-

22

-

-

120

97

-

-

-

-

-

-

Total operating expenses

4,959

3,034

204

-6,417

2,410

4,716

125

81

263

20

0

1

Loss from operations

-4,959

-3,034

-204

6,417

-2,410

-4,716

-125

-81

-263

-20

-0

-1

Investment income

-

-

-

-

8

8

-

-

-

-

-

-

Interest income

0

-

-

-

0

0

-

-

-

-

-

-

Interest expenses to a related party

17

17

-

-

9

-

-

-

-

-

-

-

Loss from operations before income tax benefit

-

-3,051

-

-

-

-4,708

-

-

-

-

-

-

Interest income

-

-

347

-

-

-

220

168

166

6

0

0

Unrealized loss on marketable securities held in Trust Account

-

-

-2

-

-

-

-19

-21

21

-17

0

0

Net loss

-4,977

-3,051

140

7,311

-2,411

-4,708

75

66

-75

-31

-0

-1

Accretion to preferred share redemption value

-

-

-

-

-899

-100

-

-

-

-

-

-

Net loss attributable to ordinary shareholders

-4,977

-3,051

-

-

-3,311

-4,808

-

-

-

-

-

-

Other comprehensive income/(loss):
Foreign currency translation adjustment, net of nil income taxes

-7

56

-

-

42

-

-

-

-

-

-

-

Unrealized gain on available for sale securities, net of nil income taxes

-

-

-

-

16

-

-

-

-

-

-

-

Less: reclassification adjustment for gain on available for sale securities realized in net income, net of nil income taxes

-

-

-

-

16

-

-

-

-

-

-

-

Total other comprehensive loss/(income)

-7

56

-

-

42

-

-

-

-

-

-

-

Comprehensive loss attributable to ordinary shareholders

-4,984

-2,995

-

-

-3,268

-4,808

-

-

-

-

-

-

Weighted average ordinary shares outstanding - basic and diluted

46,273

44,623

2,477

-78,422

42,860

42,860

2,405

2,416

2,374

1,380

1,312

1,312

Loss per share - basic and diluted

-0.11

-0.07

-

-

-0.08

-0.11

-

-

-

-

-

-

Basic and diluted net income (loss) per ordinary share

-

-

0.01

-

-

-

-0.05

-0.06

-0.10

-0.02

0.00

0.00